May 4, 2008
Submitted by art on Mon, 2008-05-05 06:36.
Indian company Glenmark Pharmaceuticals Ltd. said its Switzerland unit has completed the crucial IND-enabling pre-clinical studies for its monoclonal antibody GBR 500, used to treat multiple sclerosis, chronic obstructive pulmonary disease and inflammatory bowel disease.
A look at their posted pipeline shows one other drug for MS called GRC 4039.